News stories about TherapeuticsMD (NASDAQ:TXMD) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. TherapeuticsMD earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.8504918588044 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of equities analysts have issued reports on TXMD shares. Oppenheimer Holdings, Inc. restated an “outperform” rating and issued a $15.00 price objective on shares of TherapeuticsMD in a research report on Monday, April 17th. Stifel Nicolaus restated a “buy” rating and issued a $20.00 price objective on shares of TherapeuticsMD in a research report on Monday, April 24th. Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Wednesday, May 3rd. CIBC restated a “market perform” rating and issued a $12.00 price objective on shares of TherapeuticsMD in a research report on Tuesday, May 9th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $33.00 price objective on shares of TherapeuticsMD in a research report on Wednesday, May 10th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $16.14.

TherapeuticsMD (NASDAQ TXMD) traded up 0.96% during trading on Monday, hitting $5.25. 420,564 shares of the company’s stock were exchanged. The company’s market cap is $1.07 billion. The firm has a 50 day moving average price of $5.36 and a 200 day moving average price of $5.53. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. The firm had revenue of $4.25 million during the quarter, compared to analyst estimates of $4.91 million. TherapeuticsMD had a negative net margin of 530.84% and a negative return on equity of 71.36%. The business’s revenue was down 3.4% on a year-over-year basis. During the same quarter last year, the business earned ($0.11) EPS. On average, equities research analysts predict that TherapeuticsMD will post ($0.45) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “TherapeuticsMD (NASDAQ:TXMD) Earning Somewhat Positive News Coverage, Analysis Finds” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/therapeuticsmd-nasdaqtxmd-earning-somewhat-positive-news-coverage-analysis-finds.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Insider Buying and Selling by Quarter for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.